Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$0.12 - $0.5 $39,249 - $163,539
327,078 Added 3.59%
9,438,762 $1.23 Million
Q2 2023

Aug 14, 2023

SELL
$0.43 - $0.65 $18,944 - $28,637
-44,057 Reduced 0.48%
9,111,684 $4.65 Million
Q1 2023

May 15, 2023

BUY
$0.46 - $0.81 $3,680 - $6,480
8,000 Added 0.09%
9,155,741 $5.77 Million
Q4 2022

Feb 10, 2023

SELL
$0.5 - $261.0 $7,391 - $3.86 Million
-14,782 Reduced 0.16%
9,147,741 $5.95 Million
Q3 2022

Nov 14, 2022

SELL
$1.04 - $322.5 $138,665 - $43 Million
-133,332 Reduced 1.43%
9,162,523 $15.8 Million
Q2 2022

Aug 12, 2022

SELL
$0.41 - $1.24 $607,954 - $1.84 Million
-1,482,815 Reduced 13.76%
9,295,855 $11.5 Million
Q1 2022

May 13, 2022

SELL
$0.62 - $1.17 $530,118 - $1 Million
-855,030 Reduced 7.35%
10,778,670 $7.03 Million
Q4 2021

Feb 14, 2022

SELL
$1.09 - $1.89 $819,824 - $1.42 Million
-752,133 Reduced 6.07%
11,633,700 $12.7 Million
Q3 2021

Nov 12, 2021

SELL
$1.44 - $2.73 $4.88 Million - $9.26 Million
-3,391,633 Reduced 21.5%
12,385,833 $22.5 Million
Q2 2021

Aug 13, 2021

BUY
$2.63 - $3.67 $41.5 Million - $57.9 Million
15,777,466 New
15,777,466 $41.7 Million

Others Institutions Holding TCRT

About Alaunos Therapeutics, Inc.


  • Ticker TCRT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 216,182,000
  • Market Cap $458M
  • Description
  • Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...
More about TCRT
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.